Combinations of first-generation EGFR-TKIs, including gefitinib and erlotinib, with bevacizumab in EGFR-mutated advanced NSCLC have been explored in clinical trials (JO25567 and NEJ026 trials), and the combination has been found to yield significantly longer PFS than EGFR-TKIs alone [15,16,17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.